Success Metrics

Clinical Success Rate

72.7%

Based on 8 completed trials

Completion Rate

73%(8/11)

Active Trials

0(0%)

Results Posted

63%(5 trials)

Terminated

3(23%)

Phase Distribution

Ph phase_1

38%

Ph phase_2

31%

Ph not_applicable

Ph phase_3

23%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 1Safety & dosage

5(38.5%)

Phase 2Efficacy & side effects

4(30.8%)

Phase 3Large-scale testing

3(23.1%)

N/ANon-phased studies

1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

8 of 12 finished

Non-Completion Rate

33.3%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(8)

Terminated(4)

Other(1)

Detailed Status

Completed8

Terminated3

Withdrawn1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

72.7%

Most Advanced

Phase 3

Trials by Phase

Phase 15 (38.5%)

Phase 24 (30.8%)

Phase 33 (23.1%)

N/A1 (7.7%)

Trials by Status

terminated323%

completed862%

withdrawn18%

unknown18%

Recent Activity

0 active trials

Showing 5 of 13

terminatedphase_2

ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer

NCT01119118

withdrawnphase_2

Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer

NCT01134497

completedphase_3

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases

NCT00554229

terminatedphase_2

A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer

NCT01000948

completedphase_3

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

NCT00617669

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT01119118Phase 2

ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer

Terminated

NCT01134497Phase 2

Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer

Withdrawn

NCT00554229Phase 3

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases

Completed

NCT01000948Phase 2

A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer

Terminated

NCT00617669Phase 3

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

Completed

NCT00626548Phase 3

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

Terminated

NCT00745875Phase 2

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

Completed

NCT00713791Phase 1

Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.

Completed

NCT00710047Phase 1

Food Effect Study of a Single Dose of ZD4054 (Zibotentan)

Completed

NCT00713336Phase 1

Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval

Completed

NCT00672581Phase 1

Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment

Completed

NCT00709553Phase 1

Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)

Completed

NCT01168141Not Applicable

Window Study of ZD4054 in Metastatic Prostate Cancer

Unknown

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13